Unfortunately, the largest trials to date that used mineralocorticoid receptor antagonists and demonstrated a mortality benefit in patients with severe heart failure due to systolic LV dysfunction or acute myocardial infarction [27], [28], excluded patients with moderate to advanced CKD. This evidence concerns the gene NR3C2 and myocardial infarction.